Active AKT2 stimulation of SREBP1/SCD1-mediated lipid metabolism boosts hepatosteatosis and cancer
Translational Research · 2024-06 · 268 · 51-62
DOI: 10.1016/j.trsl.2024.01.005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Translational Research, 2024-06. Verfasst von Fuqiang Huang und 14 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Common Mechanism Research for Major Diseases, Haihe Laboratory of Cell Ecosystem, Department of Physiology, Institute of Basi…. Hauptthemen laut MEDLINE: Lipid Metabolism, Liver Neoplasms, Proto-Oncogene Proteins c-akt, Stearoyl-CoA Desaturase. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: Natural Science Foundation of Beijing Municipality, National Natural Science Foundation of China.
Abstract (Originalsprache)
Due to soared obesity population worldwide, hepatosteatosis is becoming a major risk factor for hepatocellular carcinoma (HCC). Undertaken molecular events during the progression of steatosis to liver cancer are thus under intensive investigation. In this study, we demonstrated that high-fat diet potentiated mouse liver AKT2. Hepatic AKT2 hyperactivation through gain-of-function mutation of Akt2 (Akt2E17K) caused spontaneous hepatosteatosis, injury, inflammation, fibrosis, and eventually HCC in mice. AKT2 activation also exacerbated lipopolysaccharide and D-galactosamine hydrochloride-induced injury/inflammation and N-Nitrosodiethylamine (DEN)-induced HCC. A positive correlation between AKT2 activity and SCD1 expression was observed in human HCC samples. Activated AKT2 enhanced the production of monounsaturated fatty acid which was dependent on SREBP1 upregulation of SCD1. Blockage of active SREBP1 and ablation of SCD1 reduced steatosis, inflammation, and tumor burden in DEN-treated Akt2E17K mice. Therefore, AKT2 activation is crucial for the development of steatosis-associated HCC which can be treated with blockage of AKT2-SREBP1-SCD1 signaling cascade.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Common Mechanism Research for Major Diseases, Haihe Laboratory of Cell Ecosystem, Department of Physiology, Institute of Basic Medical Sciences and School of Basic Medicine, Chinese Academy of Me…
- Institute of Cancer Stem Cell, Dalian Medical University, Dalian, China.
- Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.
- Modern Research Center for Traditional Chinese Medicine, Beijing Research Institute of Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.
- Department of Biochemistry & Molecular Biology, School of Basic Medicine, Anhui Medical University, Hefei, China.
Förderung
- Natural Science Foundation of Beijing Municipality
- National Natural Science Foundation of China
Zitieren
APA
Huang, F., Zhao, N., Cai, P., Hou, M., Yang, S., Zheng, B., Ma, Q., Jiang, J., Gai, X., Mao, Y., Wang, L., Hu, Z., Zha, X., Liu, F., & Zhang, H. (2024). Active AKT2 stimulation of SREBP1/SCD1-mediated lipid metabolism boosts hepatosteatosis and cancer. Translational Research, 268, 51-62. https://doi.org/10.1016/j.trsl.2024.01.005
Vancouver
Huang F, Zhao N, Cai P, Hou M, Yang S, Zheng B, et al. Active AKT2 stimulation of SREBP1/SCD1-mediated lipid metabolism boosts hepatosteatosis and cancer. Translational Research. 2024;268:51-62. doi:10.1016/j.trsl.2024.01.005
BibTeX
@article{Huang2024,
author = {Huang, Fuqiang and Zhao, Na and Cai, Pei and Hou, Mengjie and Yang, Shuhui and Zheng, Bohao and Ma, Qian and Jiang, Jingpeng and Gai, Xiaochen and Mao, Yilei and Wang, Lianmei and Hu, Zhongdong and Zha, Xiaojun and Liu, Fangming and Zhang, Hongbing},
title = {Active AKT2 stimulation of SREBP1/SCD1-mediated lipid metabolism boosts hepatosteatosis and cancer},
journal = {Translational Research},
year = {2024},
volume = {268},
pages = {51--62},
doi = {10.1016/j.trsl.2024.01.005}
}
EUVIMED